global glp-1 obesity drug market size forecast 2030 Goldman Sachs raises forecast: Oral enters mass market, projected to reach $114 billion by GLP-1 Weight-Loss Drugs Ride Health,
Description
For employers, these developments could lead to shifts in formulary decisions and cost-sharing strategies
How does the Precision Peptide Genetic Test help with insurance approval
Retatrutide (LY3437943) could be utilized for research on obesity, diabetes, and related conditions (such as non-alcoholic steatohepatitis, NASH)
A programme of phase 3 trials with retatrutide (TRIUMPH) is ongoing with an aim to assess the safety and efficacy of retatrutide in different populations living with obesity (OSA, T2D, established cardiovascular disease, osteoarthritis)
However, in addition to a lack or ambiguity of similar findings in humans, GLP-1 RAs are resistant to enzymatic cleavage as noted earlier (Mller et al., 2019
On the other hand, the mechanisms and changes on the longer-term GLP-1 drug scale are poorly understood
